Our medicines
Our science
Our stories
Skip to main content
Contact us
Careers
United States
Close Icon
Americas
Argentina
Spanish
Brazil
Portuguese
Canada
English
/
French
Chile
Spanish
Colombia
Spanish
Mexico
Spanish
Peru
Spanish
United States
English
Asia Pacific
Australia
English
China
Simplified Chinese
India
English
Japan
Japanese
Korea
Korean
New Zealand
English
Singapore
English
Taiwan
Traditional Chinese
Thailand
English
/
Thai
Europe
Austria
German
Belgium
English
/
Dutch
/
French
Czech Republic
Czech
Denmark
Danish
Finland
Finnish
France
French
Germany
German
Greece
Greek
Hungary
Hungarian
Ireland
English
Italy
Italian
Luxembourg
English
Netherlands
English
/
Dutch
Norway
Norwegian
Poland
Polish
Portugal
Portuguese
Romania
Romanian
Spain
Spanish
Sweden
Swedish
Switzerland
German
/
French
United Kingdom
English
Middle East
Israel
Hebrew
Saudi Arabia
English
/
Arabic
Turkey
Turkish
United Arab Emirates
English
/
Arabic
Other
Other Markets
Distributor Markets
Search
bmsUScqPageLucene
Medicines
Careers
Press Releases
Medical Information
Previous Page Icon
Previous Page Icon
Our Medicines
Patients & caregivers
Patients & caregivers
Our medicines
Survivorship Today
Patient resources
Get help paying for your medicines
Risk evaluation and mitigation strategies (REMS)
Plain language summaries of clinical trial results
CAR T cell therapy patient resources
Related links
Immunology patient resources
Our position on generic drugs
Our position on drug pricing
Psoriasis around the world
Healthcare providers
Healthcare providers
Learn about pre-approval access
Learn about post study drug access
340B practice fact sheet
Related links
U.S. medical information
Clinical trials
Researchers
Researchers
Areas of focus
In the pipeline
R&D expert voices
Our efforts in STEM
Clinical trials & research
Independent research
The Thomas O. Daniel research incubator and collaboration center
Patient safety
Related links
Research publications
Disclosure commitment
Areas of interest & research grants
Data sharing request process
Translational medicine
Investors
Investors
Stock information
Financial reporting
Analyst coverage
Events and presentations
Shareholder services
Acquisition-related information for Celgene shareholders
Investor contacts
Related links
Annual reports
Dividend history
Investment return calculator
SEC filings
Quarterly results
Business development
Business development
Our partnerships
Why partner with us
Areas of interest
Business development leadership team
Global alliances leadership team
Early innovation at BMS
Contact Business Development
Related links
Download business development brochure
Doing business with us as a supplier
News & media
News & media
Press releases
Our stories
Media library
Media contacts
Related links
Scientific media resources
Disease state resources
Corporate resources
About us
About us
Our company
Leadership
Our science
Global Inclusion & Diversity
Our impact
Working at BMS
Contact us
Related links
Global Patient Week
Our technologies
Our history
Our locations
The Bristol Myers Squibb Foundation
Resource groups
Our positions
Our Stories
Idiopathic Pulmonary Fibrosis
News and reporting on pulmonary fibrosis�a lung disease that results from scarring of lung tissue�and treatments.
Advocacy
Atrial Fibrillation (AFib)
BMS Foundation
Blood & Bone Marrow Cancer
Blood Disorders
COVID-19
Cancer
Cancer Research
Cardiovascular Research
Careers
Clinical Trials
Collaboration
Decoded by BMS
Diversity
Diversity in clinical trials
Employee Stories
Global Inclusion and Diversity
Health Equity
Her Perspective
Idiopathic Pulmonary Fibrosis
Immune-mediated
Immunotherapy
Inclusion and Engagement
International
Leadership Perspectives
Lung Cancer
Lymphoma
Neuroscience
Our Culture
Pancreatic Cancer
Patient Advocacy
Patient Perspectives
Philanthropy
Protein Degradation
Research and Development
Rheumatoid Arthritis (RA)
STEM
Science & Innovation
Science Firsthand
Sustainability
Volunteerism
May 07, 2025
Breathing new hope into pulmonary fibrosis research care
